NO20073629L - Terapeutiske formuleringer av keratinocyttvekstfaktor - Google Patents

Terapeutiske formuleringer av keratinocyttvekstfaktor

Info

Publication number
NO20073629L
NO20073629L NO20073629A NO20073629A NO20073629L NO 20073629 L NO20073629 L NO 20073629L NO 20073629 A NO20073629 A NO 20073629A NO 20073629 A NO20073629 A NO 20073629A NO 20073629 L NO20073629 L NO 20073629L
Authority
NO
Norway
Prior art keywords
growth factor
keratinocyte growth
therapeutic formulations
lyophilized
formulations
Prior art date
Application number
NO20073629A
Other languages
English (en)
Inventor
Michael J Treuheit
Vasumathi Dharmavaram
Judith Purtell
Suzanne E Roy
Original Assignee
Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab Publ filed Critical Biovitrum Ab Publ
Publication of NO20073629L publication Critical patent/NO20073629L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer langtidsstabile formuleringer av lyofilisert keratinocyttvekstfaktor og fremgangsmåter for å fremstille et lyofilisert preparat som omfatter keratinocyttvekstfaktor.
NO20073629A 2004-12-15 2007-07-13 Terapeutiske formuleringer av keratinocyttvekstfaktor NO20073629L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63621004P 2004-12-15 2004-12-15
PCT/US2005/045169 WO2006065861A2 (en) 2004-12-15 2005-12-12 Therapeutic formulations of keratinocyte growth factor

Publications (1)

Publication Number Publication Date
NO20073629L true NO20073629L (no) 2007-09-10

Family

ID=36337531

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073629A NO20073629L (no) 2004-12-15 2007-07-13 Terapeutiske formuleringer av keratinocyttvekstfaktor

Country Status (27)

Country Link
US (1) US8304387B2 (no)
EP (1) EP1827483B1 (no)
JP (1) JP5201992B2 (no)
KR (1) KR101283736B1 (no)
CN (1) CN101084008B (no)
AR (1) AR052339A1 (no)
AU (1) AU2005317166B2 (no)
BR (1) BRPI0519070A2 (no)
CA (1) CA2589889C (no)
CR (1) CR9246A (no)
DK (1) DK1827483T3 (no)
EA (1) EA013369B1 (no)
ES (1) ES2504441T3 (no)
HR (1) HRP20140926T1 (no)
IL (1) IL183435A (no)
MX (1) MX2007006822A (no)
MY (1) MY145638A (no)
NO (1) NO20073629L (no)
NZ (1) NZ555503A (no)
PL (1) PL1827483T3 (no)
PT (1) PT1827483E (no)
RS (1) RS53548B1 (no)
SI (1) SI1827483T1 (no)
TW (1) TWI351966B (no)
UA (1) UA88497C2 (no)
WO (1) WO2006065861A2 (no)
ZA (1) ZA200706095B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007006822A (es) 2004-12-15 2007-07-24 Amgen Inc Formulaciones terapeuticas para el factor de crecimiento de queratinocitos.
US20090186805A1 (en) * 2006-07-06 2009-07-23 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
KR100784134B1 (ko) * 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
CN101780269A (zh) * 2009-01-21 2010-07-21 北京三有利科技发展有限公司 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用
IT1396020B1 (it) * 2009-10-16 2012-11-09 Fitologica Srl Composizione topica a base di biopeptidi, e suo utilizzo in campo tricologico.
CN102675449B (zh) * 2011-03-17 2016-06-08 重庆富进生物医药有限公司 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途
EP2773364A1 (en) * 2011-11-02 2014-09-10 The University of Chicago Stable pharmaceutical formulations of growth factor peptides
CN102379838B (zh) * 2011-11-02 2013-06-12 广州舒泰生物技术有限公司 一种舒缓静颜化妆品的制备方法及应用
WO2013163422A1 (en) * 2012-04-25 2013-10-31 University Of Cincinnati Growth factors for the treatment of mycobacterial infection
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
EA202092926A3 (ru) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
CN108359634A (zh) * 2018-02-02 2018-08-03 江阴司特易生物技术有限公司 一种饲养细胞蛋白复合物及其应用
CN109402130A (zh) * 2018-11-23 2019-03-01 成都中医药大学附属医院 一种重组人角质细胞生长因子-1及其制备方法和用途
JP2022544442A (ja) 2019-06-24 2022-10-19 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． チューブリシン類縁体と細胞結合分子との共役体の製剤
CN110339345B (zh) * 2019-07-30 2022-11-29 重庆派金生物科技有限公司 一种重组人截短型角质细胞生长因子-1滴眼液及其制备方法和应用
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof
CN119632934A (zh) * 2025-02-19 2025-03-18 杭州熙岭生物科技有限公司 一种kgf-2组合物的冻干粉及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
DK0555205T3 (da) 1989-01-31 2001-03-05 Jeffrey S Rubin DNA, der koder for en væstfaktor, som er specifik for epitelceller
DE10399015I1 (de) * 1991-12-20 2012-05-03 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
NZ266622A (en) 1993-06-29 1997-10-24 Chiron Corp Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
EP0804479B1 (en) 1994-10-13 2006-10-11 Amgen Inc., Method of treating diabetes mellitus using kgf
US6008328A (en) 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
SI0785950T1 (en) 1994-10-13 2003-08-31 Amgen Inc. Keratinocyte growth factor analogs
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
ES2181054T3 (es) * 1996-12-06 2003-02-16 Amgen Inc Utilizacion de producto(s) proteico(s) kgf y de producto(s) proteico(s) glp-2 para la preparacion de un medicamento.
US20020012961A1 (en) * 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
EP1041996A4 (en) * 1997-12-22 2003-05-14 Human Genome Sciences Inc KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS
AU5593200A (en) * 1999-06-02 2000-12-18 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
MX2007006822A (es) 2004-12-15 2007-07-24 Amgen Inc Formulaciones terapeuticas para el factor de crecimiento de queratinocitos.

Also Published As

Publication number Publication date
DK1827483T3 (da) 2014-10-06
JP5201992B2 (ja) 2013-06-05
MX2007006822A (es) 2007-07-24
CA2589889C (en) 2013-07-30
IL183435A0 (en) 2007-09-20
CN101084008A (zh) 2007-12-05
US8304387B2 (en) 2012-11-06
EA200701293A1 (ru) 2008-02-28
TWI351966B (en) 2011-11-11
PL1827483T3 (pl) 2014-12-31
EP1827483B1 (en) 2014-07-02
TW200635603A (en) 2006-10-16
HK1115298A1 (en) 2008-11-28
AU2005317166B2 (en) 2009-09-10
US20060128622A1 (en) 2006-06-15
CN101084008B (zh) 2013-04-10
ES2504441T3 (es) 2014-10-08
ZA200706095B (en) 2008-09-25
CA2589889A1 (en) 2006-06-22
NZ555503A (en) 2010-01-29
CR9246A (es) 2007-10-23
MY145638A (en) 2012-03-15
HRP20140926T1 (hr) 2014-11-07
WO2006065861A3 (en) 2006-08-17
EP1827483A2 (en) 2007-09-05
RS53548B1 (sr) 2015-02-27
WO2006065861A2 (en) 2006-06-22
UA88497C2 (ru) 2009-10-26
AR052339A1 (es) 2007-03-14
KR20070093977A (ko) 2007-09-19
IL183435A (en) 2010-11-30
PT1827483E (pt) 2014-09-25
EA013369B1 (ru) 2010-04-30
BRPI0519070A2 (pt) 2008-12-23
JP2008524229A (ja) 2008-07-10
AU2005317166A1 (en) 2006-06-22
KR101283736B1 (ko) 2013-07-08
SI1827483T1 (sl) 2014-11-28

Similar Documents

Publication Publication Date Title
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
NO2020010I1 (no) fostamatinib eller et farmasøytisk akseptabelt salt av fostamatinib, eller et hydrat, solvat eller N-oksid av fostamatinib eller det farmasøytisk akseptable saltet av fostamatinib, spesielt fostamatinib dinatrium, eventuelt på form av et hydrat
ATE499109T1 (de) Zusammensetzung zur proteasomhemmung
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
NO20070699L (no) Spesielle aminoalkylglukosaminidfosfatforbindelser og deres anvendelse
IL214325A (en) Antibody against cmet, a drug that includes and uses it
IS7543A (is) Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær
IL183435A0 (en) Therapeutic formulations of keratinocyte growth factor
WO2006030439A3 (en) Compositions and methods for inducing hair growth
BR0305767A (pt) Métodos e composições para a preparação de derivados de ácido 4-substituìdo 3-hidroxibutìrico
FI20041704L (fi) Stabiilit mikrobisiirrosteet ja menetelmät niiden valmistamiseksi
ECSP044981A (es) Composicion oftalmica que comprende ascomicina
CY1108797T1 (el) Α-κρυσταλλικη μορφη του ρανελικου στροντιου, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις που την περιεχουν
NO20065726L (no) Forbindelser og sammensetninger for avlevering av aktive forbindelser.
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
NO20042563L (no) Preparatsammensetning som inneholder syreustabile fysiologisk aktive forbindelser og fremgangsmater til fremstilling derav
MEP34308A (en) Oral formulations of cladribine
NO20091771L (no) Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

CREP Change of representative

Representative=s name: TANDBERGS PATENTKONTOR AS, POSTBOKS 1570 VIKA, 011

FC2A Withdrawal, rejection or dismissal of laid open patent application